Italia markets closed

Adocia SA (0QAI.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
3,3758-2,7400 (-44,80%)
Alla chiusura: 06:45PM GMT
Schermo intero
Chiusura precedente6,1158
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Media VolumeN/D
Beta (5 anni mensile)1,37
Rapporto PE (ttm)N/D
EPS (ttm)-3,2240
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Adocia strengthens its cash position by 19 million euros following a real estate transaction

    The Company announces the sale of its building in Lyon in a sale and leaseback transaction worth over 20 million eurosThis transaction results in a net cash inflow of 19 million euros and is accompanied by the signature of a 12-year firm renewable leaseWith this non-dilutive transaction, Adocia has today a cash position of 28 million euros LYON, France, March 28, 2022 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris : FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the disc

  • GlobeNewswire

    Adocia announces 2021 fourth quarter financial results

    LYON, France, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its fourth quarter financial results. Fourth quarter 2021 financial results The main financial figures for the quarter are as follows: Detail of the revenue for the fourth quarter of 2021 In thousands of e

  • GlobeNewswire

    Adocia announces its financial calendar for 2022

    LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022. February 23, 2022:Publication of revenue for Q4 2021.April 19, 2022:Publication of 2021 financial statements.May 18, 202